Sequence Bio

Founded in 2013, Sequence Bio operates from St. John's, Canada, specializing in enhancing the discovery of therapies through data integration.Sequence Bio specializes in systems biology and data-driven computation to enhance the discovery of targeted therapies for both common and rare diseases. The company integrates a comprehensive array of resources, including founder population multi-omics, real-world patient data, and well-characterized phenotypes, to create customized discovery cohorts tailored to the needs of pharmaceutical and biotechnology partners. This collaborative approach facilitates the identification of disease signals that can lead to the development of more effective medicines. The primary clients of Sequence Bio include leading pharmaceutical companies and biotech firms that seek to leverage this unique platform to expedite their research and development timelines.Sequence Bio generates revenue through strategic partnerships and collaborations with pharmaceutical and biotech companies, which typically involve bespoke discovery cohort projects. These partnerships facilitate a streamlined process for conducting research and development, wherein clients benefit from tailored solutions that address specific therapeutic areas. The revenue structure is based on contractual agreements that outline project scopes, deliverables, and payment terms, reflecting the complexity and customization of the services provided. While specific pricing plans are not disclosed, the transactions encompass various models, including fixed fees for project-based services or long-term engagements that align with clients’ R&D goals. The firm is focused on launching new data-driven solutions designed for targeted therapies, with plans to enter additional markets in North America and Europe by 2025.

1. Seed

   Aug 3, 2016

   Amount

   $3M

   Investors

   Locked

2. Seed

   Oct 19, 2015

   Amount

   $1M

   Investors

   Locked